List of Docetaxel drug patents
Docetaxel is owned by Shilpa.
Docetaxel contains Docetaxel.
Docetaxel has a total of 4 drug patents out of which 0 drug patents have expired.
Docetaxel was authorised for market use on 22 December, 2015.
Docetaxel is available in injectable;injection dosage forms.
Docetaxel can be used as treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; treatment of patients with locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil; use in combination with doxorubicin and cyclophosphamide for adjuvant treatment of patients with operable node-positive breast cancer; treatment of patients with locally advanced metastatic breast cancer after failure of prior chemotherapy; use in combination with cisplatin for treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without prior chemotherapy treatment; treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer in combination with prednisone; treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil in patients that have not received prior chemotherapy, method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion, method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution.
The generics of Docetaxel are possible to be released after 30 September, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842770 | SHILPA | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
Aug, 2031
(8 years from now) | |
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(10 years from now) | |
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(10 years from now) | |
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(10 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion; Treatment of patients with locally advanced or met...
Dosage: INJECTABLE;INJECTION
DOCETAXEL family patents
11
United States
4
China
3
Singapore
3
Taiwan
2
Australia
2
Korea, Republic of
2
Canada
2
Spain
2
Malaysia
2
Japan
2
Hong Kong
2
Mexico
2
Brazil
2
South Africa
2
European Union
1
Colombia
1
AP
1
India
1
EA
1
Israel
1
New Zealand
1
Jordan
1
Ukraine
1
Philippines
1
Russia
1
Argentina
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic